RESET: A TCR-coupled antigen receptor with superior targeting sensitivity and reversible drug-regulated anti-tumor...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cells are effective cancer therapies but have limitations in certain settings.
• Improved targeting sensitivity, selectivity, and potency are needed for broader CAR T-cell efficacy.

Purpose of the Study:

• To introduce a novel receptor architecture, RESET (rapamycin-enabled, switchable endogenous T cell receptor), for enhanced T-cell therapy.
• To combine cell surface antigen targeting, small-molecule regulation, and native T-cell receptor signaling.

Main Methods:

• Development of the RESET receptor architecture integrating antigen targeting and drug-inducible control.
• Comparison of RESET-T cells with constitutive and drug-regulated CAR-T cells in preclinical models.
• Assessment of T-cell activation hallmarks and pharmacological control of T-cell states.

Main Results:

• RESET-T cells demonstrated superior performance compared to both constitutive and drug-regulated CAR-T cells.
• RESET-T cells exhibited hallmarks of native T-cell receptor (TCR) activation, suggesting improved response fidelity.
• Pharmacological control enabled toggling of T-cell activation, enhancing safety and potentially mitigating T-cell exhaustion.

Conclusions:

• The RESET architecture offers a promising approach for developing safer and more effective T-cell immunotherapies.
• This novel system may better replicate natural T-cell responses, leading to improved clinical outcomes.
• Drug-regulated targeting combined with natural immune receptor signaling holds potential for advancing cancer treatment.